Large gap with delayed quotes
|
Last quote
04/27/2026
-
16:28:33
|
Bid
04/27/2026 -
16:28:34
|
Bid Volume |
Ask
04/27/2026 -
16:28:34
|
Ask Volume |
|---|---|---|---|---|
|
3.53
+0.02
(
+0.57% )
|
3.52
|
7,400 |
3.53
|
1,900 |
Analysis date: 24.04.2026
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 14.04.2026.
Interest
Strong
Strong
Three stars since 17.04.2026.
Earnings Rev Trend
0.10
0.10
Compared to seven weeks ago, the analysts have not significantly revised their earnings per share estimates (changes between +1% and -1% are considered neutral). But the last significant trend is positive since 17.02.2026 at a price of 3.46.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 14.04.2026.
4wk Rel Perf
1.44%
1.44%
The four-week dividend-adjusted overperformance versus SP500 is 1.44%.
Sensibility
High
High
High, no change over 1 year.
Bear Market Factor
High
High
On average, the stock has a tendency to amplify the drops in the index by 3.41%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 2.58%.
Mkt Cap in $bn
1.85
1.85
With a market capitalization <$2bn, RECURSION PHARMACEUTICALS A is considered a small-cap stock.
G/PE Ratio
2.21
2.21
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
-3.35
-3.35
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
7.40%
7.40%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
7
7
Over the last seven weeks, an average of 7 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
248
248
For 1% of index variation, the stock varies on average by 2.48%.
Correlation
0.51
0.51
51.09% of stock movements are explained by index variations.
Value at Risk
1.95
1.95
The value at risk is estimated at USD 1.95. The risk is therefore 55.51%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
23.07.2021
23.07.2021